Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma

This publication has 22 references indexed in Scilit:

• Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series
  Annals of Oncology, 2000
• CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
  Blood, 2000
• Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab
  Journal of Clinical Oncology, 1999
• Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
  Journal of Clinical Oncology, 1999
• Cancer statistics, 1998
  CA: A Cancer Journal for Clinicians, 1998
• Polymerase Chain Reaction Based Gene Rearrangement Studies in the Diagnosis of Follicular Lymphoma — Performance in Formaldehyde-Fixed Tissue and Application in Clinical Problem Cases
  Pathology - Research and Practice, 1997
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs
  Cancer Biotherapy & Radiopharmaceuticals, 1997
• Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer
  New England Journal of Medicine, 1992
• Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease.
  Proceedings of the National Academy of Sciences, 1988
• Cyclophosphamide, Mitoxantrone, Vincristine and Prednisone in the Treatment of Non-Hodgkin’s Lymphoma
  Oncology, 1988